Cargando…
Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency
Somatic mutations are rare in pediatric acute myeloid leukemia (pAML), indicating that alternate strategies are needed to identify targetable dependencies. We performed the first enhancer mapping of pAML in 22 patient samples. Generally, pAML samples were distinct from adult AML samples, and MLL (KM...
Autores principales: | Perez, Monika W., Sias-Garcia, Oscar, Daramola, Alfred, Wei, Helen, Terrell, Maci, Rashid, Raushan, Park, Woojun D., Duong, Kevin, Horton, Terzah M., Li, Feng, Cherayil, Nikitha, Koren, Jost Vrabic, Gant, Vincent U., Junco, Jacob J., Curry, Choladda V., Stevens, Alexandra M., Lin, Charles Y., Yi, Joanna S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153032/ https://www.ncbi.nlm.nih.gov/pubmed/34543389 http://dx.doi.org/10.1182/bloodadvances.2020003737 |
Ejemplares similares
-
Engraftment characterization of risk-stratified AML in NSGS mice
por: Díaz de la Guardia, Rafael, et al.
Publicado: (2021) -
Momelotinib is a highly potent inhibitor of FLT3-mutant AML
por: Azhar, Mohammad, et al.
Publicado: (2022) -
Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice
por: Muranyi, Andrew, et al.
Publicado: (2022) -
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022) -
TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently
por: Kim, Han Sun, et al.
Publicado: (2023)